ENTERIC COATED DAILY LOW DOSE ASA 81 MG TABLET (DELAYED-RELEASE)
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
23-03-2022
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
ACETYLSALICYLIC ACID
Tillgänglig från:
VITA HEALTH PRODUCTS INC
ATC-kod:
B01AC06
INN (International namn):
ACETYLSALICYLIC ACID
Dos:
81MG
Läkemedelsform:
TABLET (DELAYED-RELEASE)
Sammansättning:
ACETYLSALICYLIC ACID 81MG
Administreringssätt:
ORAL
Enheter i paketet:
30/120/180/300
Receptbelagda typ:
OTC
Terapiområde:
SALICYLATES
Produktsammanfattning:
Active ingredient group (AIG) number: 0101169013; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2011-02-17
Produktens egenskaper
ASA 81 mg Page 1 of 46
PRODUCT MONOGRAPH
ASA 81 MG
Acetylsalicylic Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg, MB
Canada R2J 3W2
Control Number: 261087
Date of Preparation:
February 3, 2011
Date of Revision :
March 23, 2022
ASA 81 mg Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
...............................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................
9
OVERDOSAGE
...........................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
11
STORAGE AND STABILITY
.....................................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
.....................................................................................
14
CLINICAL TRIALS
..............
Läs hela dokumentet
